Virtu Financial LLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Virtu Financial LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the third quarter, HoldingsChannel reports. The institutional investor purchased 7,587 shares of the biopharmaceutical company’s stock, valued at approximately $434,000.

A number of other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after purchasing an additional 30,901 shares in the last quarter. Congress Asset Management Co. lifted its holdings in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Halozyme Therapeutics by 9.7% in the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock valued at $43,002,000 after purchasing an additional 72,544 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total transaction of $620,300.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,778,084.68. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 40,000 shares of company stock valued at $2,242,100 over the last 90 days. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $48.00 on Monday. The business’s 50 day moving average price is $51.43 and its two-hundred day moving average price is $54.07. The company has a market cap of $6.11 billion, a PE ratio of 15.89, a price-to-earnings-growth ratio of 0.43 and a beta of 1.23. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Piper Sandler boosted their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $58.00 to $62.00 in a report on Monday, October 7th. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.